{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T20:05:04Z","timestamp":1787601904260,"version":"build-2736575974"},"reference-count":108,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T00:00:00Z","timestamp":1654992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Cancer cachexia syndrome (CCS) is a multifactorial metabolic syndrome affecting a significant proportion of patients. CCS is characterized by progressive weight loss, alterations of body composition and a systemic inflammatory status, which exerts a major impact on the host\u2019s innate and adaptive immunity. Over the last few years, the development of immune checkpoint inhibitors (ICIs) transformed the treatment landscape for a wide spectrum of malignancies, creating an unprecedented opportunity for long term remissions in a significant subset of patients. Early clinical data indicate that CCS adversely impairs treatment outcomes of patients receiving ICIs. We herein reviewed existing evidence on the potential links between the mechanisms that promote the catabolic state in CCS and those that impair the antitumor immune response. We show that the biological mediators and processes leading to the development of CCS may also participate in the modulation and the sustainment of an immune suppressive tumor microenvironment and impaired anti-tumor immunity. Moreover, we demonstrate that the deregulation of the host\u2019s metabolic homeostasis in cancer cachexia is associated with resistance to ICIs. Further research on the interrelation between cancer cachexia and anti-tumor immunity is required for the effective management of resistance to immunotherapy in this specific but large subgroup of ICI treated individuals.<\/jats:p>","DOI":"10.3390\/life12060880","type":"journal-article","created":{"date-parts":[[2022,6,12]],"date-time":"2022-06-12T09:26:48Z","timestamp":1655026008000},"page":"880","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cancer Cachexia and Antitumor Immunity: Common Mediators and Potential Targets for New Therapies"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6643-9855","authenticated-orcid":false,"given":"Konstantinos","family":"Rounis","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, University General Hospital, 71110 Heraklion, Crete, Greece"},{"name":"Theme Cancer, Karolinska University Hospital\/Department of Oncology-Pathology, Karolinska Institutet, 17164 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3258-2984","authenticated-orcid":false,"given":"Dimitrios","family":"Makrakis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University General Hospital, 71110 Heraklion, Crete, Greece"},{"name":"Department of Medicine, Division of Oncology, University of Washington, Seattle, WA 98195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Gioulbasanis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Animus Kyanus Stavros General Clinic, 41222 Larissa, Thessaly, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8343-6226","authenticated-orcid":false,"given":"Simon","family":"Ekman","sequence":"additional","affiliation":[{"name":"Theme Cancer, Karolinska University Hospital\/Department of Oncology-Pathology, Karolinska Institutet, 17164 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"De Petris","sequence":"additional","affiliation":[{"name":"Theme Cancer, Karolinska University Hospital\/Department of Oncology-Pathology, Karolinska Institutet, 17164 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Mavroudis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University General Hospital, 71110 Heraklion, Crete, Greece"},{"name":"Laboratory of Translational Oncology, School of Medicine, University of Crete, 70013 Heraklion, Crete, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Agelaki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University General Hospital, 71110 Heraklion, Crete, Greece"},{"name":"Laboratory of Translational Oncology, School of Medicine, University of Crete, 70013 Heraklion, Crete, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"18","author":"Baracos","year":"2018","journal-title":"Nat. Rev. Dis. Primers."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","article-title":"Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review","volume":"57","author":"Shachar","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: Mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab."},{"key":"ref_4","first-page":"629","article-title":"Systemic Inflammation in Cachexia\u2014Is Tumor Cytokine Expression Profile the Culprit?","volume":"6","author":"Lima","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-18-0415","article-title":"Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance","volume":"24","author":"Turner","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40425-019-0512-5","article-title":"Complex inter-relationship of body mass index, gender and serum creatinine on survival: Exploring the obesity paradox in melanoma patients treated with checkpoint inhibition","volume":"7","author":"Naik","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.21037\/tlcr-21-460","article-title":"Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors: Results from a prospective, observational study","volume":"10","author":"Rounis","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/infdis\/157.3.413","article-title":"Cachectin: A hormone that triggers acute shock and chronic cachexia","volume":"157","author":"Tracey","year":"1988","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"188359","DOI":"10.1016\/j.bbcan.2020.188359","article-title":"Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions","volume":"1873","author":"Siddiqui","year":"2020","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.bbalip.2015.08.008","article-title":"Regulation of hepatic cardiolipin metabolism by TNF\u03b1: Implication in cancer cachexia","volume":"1851","author":"Peyta","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1084\/jem.20111020","article-title":"Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis","volume":"208","author":"Braun","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1096\/fasebj.3.8.2721856","article-title":"Anticachectin\/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models","volume":"3","author":"Sherry","year":"1989","journal-title":"FASEB J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1093\/jnci\/89.23.1763","article-title":"Biology of cachexia","volume":"89","author":"Tisdale","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_15","first-page":"1355","article-title":"Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients","volume":"21","author":"Karayiannakis","year":"2001","journal-title":"Anticancer. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/BF01262570","article-title":"Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients","volume":"5","author":"Maltoni","year":"1997","journal-title":"Support Care Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/cncr.22944","article-title":"A placebo-controlled double blind trial of etanercept for the cancer anorexia\/weight loss syndrome: Results from N00C1 from the North Central Cancer Treatment Group","volume":"110","author":"Jatoi","year":"2007","journal-title":"Cancer"},{"key":"ref_18","first-page":"18","article-title":"A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia","volume":"6","author":"Wiedenmann","year":"2008","journal-title":"J. Support Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients with Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.abb.2014.12.026","article-title":"Endurance training prevents TWEAK but not myostatin-mediated cardiac remodelling in cancer cachexia","volume":"567","author":"Oliveira","year":"2015","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.cell.2015.08.031","article-title":"Targeting of Fn14 Prevents Cancer-Induced Cachexia and Prolongs Survival","volume":"162","author":"Johnston","year":"2015","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.cell.2005.09.022","article-title":"TWEAK attenuates the transition from innate to adaptive immunity","volume":"123","author":"Maecker","year":"2005","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5737159","DOI":"10.1155\/2017\/5737159","article-title":"Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells","volume":"2017","author":"Ye","year":"2017","journal-title":"J. Immunol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/1078-0432.CCR-14-1334","article-title":"A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers","volume":"21","author":"Lassen","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/1535-7163.MCT-17-0330","article-title":"Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors","volume":"17","author":"Lam","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/SPC.0000000000000398","article-title":"Targeting IL-1\u03b1 in cancer cachexia: A narrative review","volume":"12","author":"McDonald","year":"2018","journal-title":"Curr. Opin. Support Palliat. Care"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0304-3835(95)03858-T","article-title":"Interleukin-1 receptor antagonist (IL-1ra) is unable to reverse cachexia in rats bearing an ascites hepatoma (Yoshida AH-130)","volume":"95","author":"Costelli","year":"1995","journal-title":"Cancer Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/ijc.2910510526","article-title":"Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer","volume":"51","author":"Douvdevani","year":"1992","journal-title":"Int. J. Cancer"},{"key":"ref_30","first-page":"1029","article-title":"Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression","volume":"59","author":"Voronov","year":"1999","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1593\/neo.11332","article-title":"Interleukin 1\u03b1 sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts","volume":"13","author":"Tjomsland","year":"2011","journal-title":"Neoplasia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41590-018-0066-6","article-title":"A tumor-myeloid cell axis, mediated via the cytokines IL-1\u03b1 and TSLP, promotes the progression of breast cancer","volume":"19","author":"Kuan","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1470-2045(17)30006-2","article-title":"MABp1 as a novel antibody treatment for advanced colorectal cancer: A randomised, double-blind, placebo-controlled, phase 3 study","volume":"18","author":"Hickish","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.clnu.2011.07.010","article-title":"Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia?","volume":"31","author":"Watt","year":"2012","journal-title":"Clin. Nutr."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1002\/eji.201041037","article-title":"IL-1\u03b2 regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function","volume":"40","author":"Elkabets","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Oh, K., Lee, O.-Y., Park, Y., Seo, M.W., and Lee, D.-S. (2016). IL-1\u03b2 induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2746-7"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"12994","DOI":"10.1073\/pnas.1705165114","article-title":"Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth","volume":"114","author":"Voigt","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1073\/pnas.1812266115","article-title":"Blocking IL-1\u03b2 reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation","volume":"116","author":"Kaplanov","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"ref_41","first-page":"1091","article-title":"Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: Relationship to acute phase response and survival","volume":"21","author":"Moses","year":"2009","journal-title":"Oncol. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"R393","DOI":"10.1152\/ajpregu.00716.2007","article-title":"Interleukin-6 and cachexia in ApcMin\/+ mice","volume":"294","author":"Baltgalvis","year":"2008","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.immuni.2005.09.010","article-title":"IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells","volume":"23","author":"Kitamura","year":"2005","journal-title":"Immunity"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1074-7613(00)00078-9","article-title":"Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1","volume":"13","author":"Diehl","year":"2000","journal-title":"Immunity"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1158\/0008-5472.CAN-16-2446","article-title":"Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression","volume":"77","author":"Tsukamoto","year":"2017","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"15053","DOI":"10.1073\/pnas.2433717100","article-title":"CD4 T cell memory derived from young naive cells functions well into old age, but memory generated from aged naive cells functions poorly","volume":"100","author":"Haynes","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/2326-6066.CIR-16-0073","article-title":"Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1158\/0008-5472.CAN-18-0118","article-title":"Combined Blockade of IL6 and PD-1\/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment","volume":"78","author":"Tsukamoto","year":"2018","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.12659\/MSM.907439","article-title":"Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model","volume":"24","author":"Li","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e1249559","DOI":"10.1080\/2162402X.2016.1249559","article-title":"Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab","volume":"5","author":"Damuzzo","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fimmu.2012.00188","article-title":"Chemokines, selectins and intracellular calcium flux: Temporal and spatial cues for leukocyte arrest","volume":"3","author":"Dixit","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/01635581.2012.630157","article-title":"Baseline plasma levels of interleukin-8 in stage IV non-small-cell lung cancer patients: Relationship with nutritional status and prognosis","volume":"64","author":"Gioulbasanis","year":"2012","journal-title":"Nutr. Cancer."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Hou, Y.-C., Wang, C.-J., Chao, Y.-J., Chen, H.-Y., Wang, H.-C., Tung, H.-L., Lin, J.-T., and Shan, Y.-S. (2018). Elevated Serum Interleukin-8 Level Correlates with Cancer-Related Cachexia and Sarcopenia: An Indicator for Pancreatic Cancer Outcomes. J. Clin. Med., 7.","DOI":"10.3390\/jcm7120502"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/ijc.28770","article-title":"Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17\u2014A new mechanism of impaired antitumor immunity","volume":"135","author":"Mishalian","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1093\/annonc\/mdx190","article-title":"Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients","volume":"28","author":"Sanmamed","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2018.36.15_suppl.3091","article-title":"Phase I trial of BMS-986253, an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors","volume":"36","author":"Collins","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1210\/jc.2014-4318","article-title":"Role of Activin A and myostatin in human cancer cachexia","volume":"100","author":"Loumaye","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/jcsm.12145","article-title":"Activin A induces skeletal muscle catabolism via p38\u03b2 mitogen-activated protein kinase","volume":"8","author":"Ding","year":"2017","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jcsm.12209","article-title":"Circulating Activin A predicts survival in cancer patients","volume":"8","author":"Loumaye","year":"2017","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1084\/jem.20082603","article-title":"Activin-A induces regulatory T cells that suppress T helper cell immune responses and protect from allergic airway disease","volume":"206","author":"Semitekolou","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.4049\/jimmunol.177.10.6787","article-title":"Activin A functions as a Th2 cytokine in the promotion of the alternative activation of macrophages","volume":"177","author":"Ogawa","year":"2006","journal-title":"J. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"eaat7527","DOI":"10.1126\/scisignal.aat7527","article-title":"Therapeutic blockade of Activin-A improves NK cell function and antitumor immunity","volume":"12","author":"Rautela","year":"2019","journal-title":"Sci. Signal."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-19-1065","article-title":"First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors","volume":"25","author":"Tao","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_68","first-page":"3590","article-title":"Transforming Growth Factor \u03b21 Induces Cachexia and Systemic Fibrosis without an Antitumor Effect in Nude Mice","volume":"51","author":"Zugmaier","year":"1991","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nm.3961","article-title":"Excess TGF-\u03b2 mediates muscle weakness associated with bone metastases in mice","volume":"21","author":"Waning","year":"2015","journal-title":"Nat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/jcsm.12441","article-title":"Tumour-derived transforming growth factor-\u03b2 signalling contributes to fibrosis in patients with cancer cachexia","volume":"10","author":"Lima","year":"2019","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming Growth Factor-\u03b2 Signaling in Immunity and Cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12967-019-1967-3","article-title":"Blockade of TGF-\u03b2 signaling to enhance the antitumor response is accompanied by dysregulation of the functional activity of CD4+CD25+Foxp3+ and CD4+CD25-Foxp3+ T cells","volume":"17","author":"Polanczyk","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/jcsm.12077","article-title":"MAP3K11\/GDF15 axis is a critical driver of cancer cachexia","volume":"7","author":"Lerner","year":"2016","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/nm1677","article-title":"Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1","volume":"13","author":"Johnen","year":"2007","journal-title":"Nat. Med."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Zhou, Z., Li, W., Song, Y., Wang, L., Zhang, K., Yang, J., Zhang, W., Su, H., and Zhang, Y. (2013). Growth differentiation factor-15 suppresses maturation and function of dendritic cells and inhibits tumor-specific immune response. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0078618"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1158\/1078-0432.CCR-10-0705","article-title":"GDF-15 contributes to proliferation and immune escape of malignant gliomas","volume":"16","author":"Roth","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1172\/JCI91561","article-title":"NF-\u03baB regulates GDF-15 to suppress macrophage surveillance during early tumor development","volume":"127","author":"Ratnam","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/s41591-020-0945-x","article-title":"Antibody-mediated inhibition of GDF15\u2013GFRAL activity reverses cancer cachexia in mice","volume":"26","author":"Suriben","year":"2020","journal-title":"Nat. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3892\/or.2012.1812","article-title":"Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer","volume":"28","author":"Ohki","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.4049\/jimmunol.1302895","article-title":"Novel role for tumor-induced expansion of myeloid-derived cells in cancer cachexia","volume":"192","author":"Cuenca","year":"2014","journal-title":"J. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"eaay1863","DOI":"10.1126\/sciimmunol.aay1863","article-title":"Targeted deletion of PD-1 in myeloid cells induces antitumor immunity","volume":"5","author":"Strauss","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1582-4934.2010.01044.x","article-title":"Tumour-associated fibroblasts and mesenchymal stem cells: More similarities than differences","volume":"15","author":"Paunescu","year":"2011","journal-title":"J. Cell. Mol. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1084\/jem.20122344","article-title":"Depletion of stromal cells expressing fibroblast activation protein-\u03b1 from skeletal muscle and bone marrow results in cachexia and anemia","volume":"210","author":"Roberts","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.trecan.2016.07.005","article-title":"Cachexia & Brown Fat: A Burning Issue in Cancer","volume":"2","author":"Kir","year":"2016","journal-title":"Trends Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fimmu.2018.00414","article-title":"Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts","volume":"9","author":"Ziani","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/emmm.201200231","article-title":"P-selectin genotype is associated with the development of cancer cachexia","volume":"4","author":"Tan","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/jcsm.12138","article-title":"New genetic signatures associated with cancer cachexia as defined by low skeletal muscle index and weight loss","volume":"8","author":"Johns","year":"2017","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nri1351","article-title":"Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation","volume":"4","author":"Ley","year":"2004","journal-title":"Nat. Rev. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1073\/pnas.261704098","article-title":"Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis","volume":"99","author":"Borsig","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.immuni.2016.04.015","article-title":"PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion","volume":"44","author":"Tinoco","year":"2016","journal-title":"Immunity"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1083\/jcb.119.2.301","article-title":"Autophagy in yeast demonstrated with proteinase-deficient mutants and conditions for its induction","volume":"119","author":"Takeshige","year":"1992","journal-title":"J. Cell. Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"30340","DOI":"10.1038\/srep30340","article-title":"Autophagy is induced in the skeletal muscle of cachectic cancer patients","volume":"6","author":"Aversa","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"26991","DOI":"10.1038\/srep26991","article-title":"Aerobic Exercise and Pharmacological Treatments Counteract Cachexia by Modulating Autophagy in Colon Cancer","volume":"31","author":"Pigna","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41598-017-02088-2","article-title":"Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling","volume":"7","author":"Pettersen","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/carcin\/bgr031","article-title":"The multiple roles of autophagy in cancer","volume":"32","author":"Rosenfeldt","year":"2011","journal-title":"Carcinogenesis"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.it.2012.06.003","article-title":"Autophagy in the regulation of pathogen replication and adaptive immunity","volume":"33","author":"Randow","year":"2012","journal-title":"Trends Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"429","DOI":"10.4161\/auto.22969","article-title":"\u03b1-TEA as a stimulator of tumor autophagy and enhancer of antigen cross-presentation","volume":"9","author":"Hahn","year":"2013","journal-title":"Autophagy"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.4049\/jimmunol.0801143","article-title":"Autophagy is essential for mitochondrial clearance in mature T lymphocytes","volume":"182","author":"Pua","year":"2009","journal-title":"J. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/ni.3365","article-title":"Autophagy enforces functional integrity of regulatory T cells by coupling environmental cues and metabolic homeostasis","volume":"17","author":"Wei","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/15548627.2015.1009787","article-title":"Impaired macrophage autophagy increases the immune response in obese mice by promoting proinflammatory macrophage polarization","volume":"11","author":"Liu","year":"2015","journal-title":"Autophagy"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1189\/jlb.3HI0715-305R","article-title":"High-mobility group box protein 1 promotes the survival of myeloid-derived suppressor cells by inducing autophagy","volume":"100","author":"Parker","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jamaoncol.2019.5241","article-title":"Association Between Body Mass Index and Overall Survival with Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer","volume":"6","author":"Kichenadasse","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cncr.32576","article-title":"Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials","volume":"126","author":"Martini","year":"2020","journal-title":"Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/s41598-019-39120-6","article-title":"Impact of sarcopenia in patients with advanced non\u2013small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study","volume":"9","author":"Shiroyama","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2020.03.003","article-title":"Cachexia\u2014Sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors","volume":"143","author":"Roch","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/jcsm.12538","article-title":"Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma","volume":"11","author":"Chu","year":"2020","journal-title":"J. Cachexia Sarcopenia Muscle"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/6\/880\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:28:29Z","timestamp":1760138909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/12\/6\/880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,12]]},"references-count":108,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["life12060880"],"URL":"https:\/\/doi.org\/10.3390\/life12060880","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,12]]}}}